Mehdi Shahidi

Research interests

Publications

• Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30033-x

• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(14)71173-8

• Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.44.2806

• Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.1764

• Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70086-4

• LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.30.15_suppl.lba7500

• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70087-6

Current projects

No projects listed.